Nektar Therapeutics (NKTR) — Capital Reinvestment Ratio
Nektar Therapeutics (NKTR) has a Capital Reinvestment Ratio of 0.00x as of June 2018, meaning it reinvests 0% of its operating cash flow ($959.64 Million) in capital expenditures ($2.75 Million). Check tangible net worth ratio of Nektar Therapeutics to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nektar Therapeutics Capital Reinvestment Ratio (1997–2018)
This chart tracks Nektar Therapeutics's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see Nektar Therapeutics (NKTR) cash conversion ratio.
Annual Capital Reinvestment Ratio for Nektar Therapeutics (1997–2018)
Year-by-year Capital Reinvestment Ratio for Nektar Therapeutics from 1997 to 2018. See free cash flow generation of Nektar Therapeutics to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 0.02x | $718.21 Million | $14.24 Million | ▼ -96.2% |
| 2009 | 0.52x | $39.74 Million | $20.70 Million | ▲ +132.4% |
| 2007 | 0.22x | $146.30 Million | $32.80 Million | ▼ -93.5% |
| 1997 | 3.47x | $4.98 Million | $17.26 Million | — |